Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy

Pharmacogenomics

Volumn 14, Issue 1, 2013, Pages 35-45

  Puranik, Yogita Ghodke ^a   Birnbaum, Angela K ^a   Marino, Susan E ^a   Ahmed, Ghada ^a   Cloyd, James C ^a   Remmel, Rory P ^a   Leppik, Ilo E ^a,b,c   Lamba, Jatinder K ^a,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c MINCEP Epilepsy Care   (United States)

^d PUMA Institute of Personalized Medicine   (United States)

Author keywords

ABCB1; ABCC2; carbamazepine; CYP3A4; EPHX1; pharmacogenomics; pharmacokinetics; UGT2B7

Indexed keywords

10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; ABC TRANSPORTER; ABC TRANSPORTER C2; ADENINE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CELL RECEPTOR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOSINE; EPOXIDE HYDROLASE; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 2B7; GUANINE; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEAR RECEPTOR NR1I1; THYMINE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ABCB1 GENE; ABCC2 GENE; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; CYP3A4 GENE; CYP3A5 GENE; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSPORT; EPHX1 GENE; EPILEPSY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NR1I2 GENE; PROMOTER REGION; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UGT2B7 GENE;

ANTICONVULSANTS; BIOLOGICAL TRANSPORT; CARBAMAZEPINE; CYTOCHROME P-450 CYP3A; EPILEPSY; EPOXIDE HYDROLASES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, STEROID;

EID: 84871405336     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.180     Document Type: Article

References (48)

1. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 17(2), 149-173, discussion 147 (2003). (Pubitemid 36753531)
2. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry 159(Suppl. 4), S1-S50 (2002).
3. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 28(Suppl. 3), S64-S70 (1987). (Pubitemid 18021823)
4. Durelli L, Massazza U, Cavallo R. Carbamazepine toxicity and poisoning. Incidence, clinical features and management. Med. Toxicol. Adv. Drug Exp. 4(2), 95-107 (1989). (Pubitemid 19089281)
5. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J. Clin. Invest. 82(6), 1826-1832 (1988). (Pubitemid 19054926)
6. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch. Intern. Med. 155(21), 2285-2290 (1995).
7. Ganeva M, Gancheva T, Lazarova R et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int. J. Dermatol. 47(8), 853-860 (2008).
8. Hung SI, Chung WH, Liu ZS et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11(3), 349-356 (2010).
9. Ufer M, Mosyagin I, Muhle H et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C T polymorphism in young and adult patients with epilepsy. Pharmacogenet. Genomics 19(5), 353-362 (2009).
10. Sisodiya SM, Goldstein DB. Drug resistance in epilepsy: more twists in the tale. Epilepsia 48(12), 2369-2370 (2007). (Pubitemid 350243407)
11. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 42(10), 1255-1260 (2001). (Pubitemid 33070664)
12. Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16(4), 297-306 (2006).
13. Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome .: ethnicity matters. Pharmacogenomics J. 6(4), 265-268 (2006). (Pubitemid 44137953)
14. Man CB, Kwan P, Baum L et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48(5), 1015-1018 (2007). (Pubitemid 46763406)
15. Eichelbaum M, Ekbom K, Bertilsson L, Ringberger VA, Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur. J. Clin. Pharmacol. 8(5), 337-341 (1975).
16. Rawlins MD, Collste P, Bertilsson L, Palmer L. Distribution and elimination kinetics of carbamazepine in man. Eur. J. Clin. Pharmacol. 8(2), 91-96 (1975).
17. Albright PS, Bruni J. Effects of carbamazepine and its epoxide metabolite on amygdala-kindled seizures in rats. Neurology 34(10), 1383-1386 (1984). (Pubitemid 14047257)
18. Bourgeois BF, Wad N. Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children. Ther. Drug Monit. 6(3), 259-265 (1984). (Pubitemid 14037114)
19. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin. Pharmacokinet. 11(3), 177-198 (1986). (Pubitemid 16079738)
20. Bu HZ, Kang P, Deese AJ, Zhao P, Pool WF. Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine. Drug Metab. Dispos. 33(12), 1920-1924 (2005). (Pubitemid 41697278)
21. Pelkonen O, Myllynen P, Taavitsainen P et al. Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31(6), 321-343 (2001). (Pubitemid 32679311)
22. Zhang C, Zuo Z, Kwan P, Baum L. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 52(10), 1894-1904 (2011).
23. Kim WJ, Lee JH, Yi J et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet. Genomics 20(4), 249-256 (2010).
24. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12(16), 3557-3560 (2001). (Pubitemid 33065498)
25. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52(2), 333-346 (2007). (Pubitemid 46123353)
26. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. Carbamazepine is not a substrate for P-glycoprotein. Br. J. Clin. Pharmacol. 51(4), 345-349 (2001). (Pubitemid 32391490)
27. Luna-Tortos C, Fedrowitz M, Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 55(8), 1364-1375 (2008).
28. Luna-Tortos C, Fedrowitz M, Loscher W. Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 58(7), 1019-1032 (2010).
29. Hung CC, Jen Tai J, Kao PJ, Lin MS, Liou HH. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 8(9), 1151-1158 (2007).
30. Simon C, Stieger B, Kullak-Ublick GA et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol. Scand. 115(4), 232-242 (2007). (Pubitemid 46449584)
31. Marino SE, Birnbaum AK, Leppik IE et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin. Pharmacol. Ther. 91(3), 483-488 (2012).
32. Diczfalusy U, Miura J, Roh HK et al. 4b-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet. Genomics 18(3), 201-208 (2008). (Pubitemid 351323234)
33. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50(2), 222-239 (1995).
34. Zhu B, Liu ZQ, Chen GL et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br. J. Clin. Pharmacol. 55(3), 264-269 (2003). (Pubitemid 36390756)
35. Schwartz JB. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42(2), 107-121 (2003). (Pubitemid 36188552)
36. Pearce RE, Lu W, Wang Y, Uetrecht JP, Correia MA, Leeder JS. Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab. Dispos. 36(8), 1637-1649 (2008).
37. Sachse C, Smith G, Wilkie MJ et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23(11), 1839-1849 (2002). (Pubitemid 35363272)
38. Nakajima Y, Saito Y, Shiseki K et al. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur. J. Clin. Pharmacol. 61(1), 25-34 (2005). (Pubitemid 40558276)
39. Makmor-Bakry M, Sills GJ, Hitiris N, Butler E, Wilson EA, Brodie MJ. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clin. Neuropharmacol. 32(4), 205-212 (2009).
40. Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav. 21(1), 27-30 (2011).
41. Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348(15), 1442-1448 (2003). (Pubitemid 36407173)
42. Ufer M, Von Stulpnagel C, Muhle H et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet. Genomics 21(10), 624-630 (2011).
43. Perucca E, Johannessen SI. The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? Epileptic Dis. 5(Suppl. 1), S17-S26 (2003). (Pubitemid 36818440)
44. Fagiolino P, Vazquez M, Eiraldi R, Maldonado C, Scaramelli A. Influence of efflux transporters on drug metabolism: theoretical approach for bioavailability and clearance prediction. Clin. Pharmacokinet. 50(2), 75-80 (2011).
45. Haerian BS, Lim KS, Mohamed EH et al. Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. Seizure 20(5), 387-394 (2011).
46. Lamba V, Panetta JC, Strom S, Schuetz EG. Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J. Pharmacol. Exp. Ther. 332(3), 1088-1099 (2010).
47. Staines AG, Coughtrie MW, Burchell B. N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J. Pharmacol. Exp. Ther. 311(3), 1131-1137 (2004). (Pubitemid 39612720)
48. Innocenti F, Liu W, Fackenthal D et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP- glucuronosyltransferase 2B7 gene. Pharmacogenet. Genomics 18(8), 683-697 (2008).